These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 15782313)

  • 21. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
    Rao S; Cunningham D; Price T; Hill ME; Ross PJ; Tebbutt N; Norman AR; Oates J; Shellito P
    Br J Cancer; 2004 Aug; 91(5):839-43. PubMed ID: 15266319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
    Shin SJ; Jeung HC; Ahn JB; Choi HJ; Cho BC; Rha SY; Yoo NC; Roh JK; Chung HC
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):157-65. PubMed ID: 17426971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
    J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
    Massacesi C; La Cesa A; Marcucci F; Pilone A; Rocchi MB; Zepponi L; Santini D; Tonini G; Burattini L
    Oncology; 2006; 70(4):294-300. PubMed ID: 17047400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
    Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G
    Oncology; 2005; 69(1):27-34. PubMed ID: 16088232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Dong N; Jiang W; Li H; Liu Z; Xu X; Wang M
    Am J Clin Oncol; 2009 Dec; 32(6):559-63. PubMed ID: 19581793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
    Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
    Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
    Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
    Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
    Larsen FO; Boisen MK; Fromm AL; Jensen BV
    Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer.
    Ardavanis AS; Ioannidis GN; Orphanos GS; Rigatos GA
    Anticancer Res; 2006; 26(2B):1669-72. PubMed ID: 16619589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
    Gelibter AJ; Gamucci T; Pollera CF; Di Costanzo F; Nuzzo C; Gabriele A; Signorelli C; Gasperoni S; Ferraresi V; Giannarelli D; Cognetti F; Zeuli M
    Curr Med Res Opin; 2007 Sep; 23(9):2117-23. PubMed ID: 17651538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.